Academic literature on the topic 'WG 3000'

Bacterial spot, caused by Xanthomonas cucurbitae, has become one of the most important diseases of pumpkin. Seventeen chemical compounds and five biocontrol agents were evaluated for their efficacy for management of the disease. The EC50 for reduction in cell multiplication of the pathogen ranged from 0.17 ppm for mancozeb (Dithane 75 DF) to 64.53 ppm for cuprous oxide (Nordox 75 WG) in nutrient broth, and from 0.23 ppm for Dithane 75 DF to 38.87 ppm Nordox 75 WG in casitone yeast extract broth. The inhibition zones produced by biocontrol agents on Luria Bertani culture medium ranged from 3.1 mm for Bacillus pumilus (Sonata ASO) to 10.6 mm for Streptomyces lydicus (Actinovate AG). In the field trials, copper oxychloride + copper hydroxide (Badge X2 DF), copper sulfate (Cuprofix Ultra 40 DF), oxytetracycline (Mycoshield 40 WSP), copper sulfate pentahydrate (Phyton-016B), copper hydroxide (Kocide-3000 46.1 DF) plus acibenzolar-s-methyl (ActiGard 50 WG), Kocide-3000 46.1 DF plus famoxadone + cymoxanil (Tanos 50D WG), an extract from Reynoutria sachalinensis (Regalia), and B. subtilis (Serenade ASO) were more effective in reducing incidence and severity of bacterial spot on both leaves and fruit compared to controls. These chemical compounds or biocontrol agents may be used in combination with other methods to manage X. cucurbitae in pumpkin. Accepted for publication 19 April 2016. Published 9 May 2016.

The objective of this study was to evaluate the effect of exogenous emulsifier and lipase in diets on performance, digestibility, and organ biometry of broiler chickens. A completely randomised design with seven treatments and seven replications was adopted. The treatments were as follows: T1 (positive control; PC): 3000, 3100, 3200, and 3250 Kcal of metabolisable energy (ME) kg-1 of diet for phases 1 to 10, 11 to 21, 22 to 31, and 32 to 37 days, respectively; T2: PC with reduction in ME of 30 Kcal kg-1 of diet; T3: PC with reduction in ME of 60 Kcal kg-1 of feed; T4 (negative control; NC): PC with reduction in ME of 90 Kcal kg-1 of feed; T5: NC with inclusion of exogenous lipase (10 000 U kg-1); T6: NC with inclusion of emulsifier (250 g t-1); and T7: NC with inclusion of lipase (10 000 U kg-1) and emulsifier (250 g t-1) in the period from 1 to 37 days of rearing. Performance characteristics (weight gain (WG), feed intake (FI), and feed conversion (FC)), carcass yield, cut yield, the relative weight of abdominal fat and organs (small intestine, liver, and pancreas), and relative intestinal length, in addition to dry matter digestibility (CDADM), ethereal extract (CDAEE), crude metabolisable energy (CMACE), and apparent metabolisable energy (AME) of the diets, were evaluated. In the initial phase, the CDAEE was higher for the PC group than for the emulsifier + lipase group. The AME determined in the final phase for the group supplemented with an emulsifier was higher by approximately 50 Kcal (EM) than the NC group. The WG of the lipase group was similar to that of the PC group. However, the groups with emulsifier and emulsifier + lipase showed a lower WG than the PC group. The additives used did not recover the FC to the same level observed in the PC group. The reduction in ME of 90 Kcal kg-1 generated a lower WG and worse FC. The use of both an emulsifier and lipase together produced results like to the PC group. The biometrics of the organs and the carcass yield and cuts were not influenced by diets. Thus, it can be concluded that the inclusion of lipase and an emulsifier improves the performance of broilers given diets with reduced energy, although it does not improve the lipid utilisation of the diets.

Abstract Abstract 4410 BACKGROUND Autoimmune cytopenia occurs in 5%-10% of patients with CLL. Treatment for patients with both autoimmune cytopenia and progressive CLL is challenging due to poor tolerance of myelosuppression, and the risk of exacerbation of autoimmune cytopenia by purine analogues. METHODS We identified 20 patients from our CLL database of approximately 3000 patients who were treated with a chemoimmunotherapy regimen of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) for both autoimmune cytopenia and progressive CLL from January 2000-December 2008 at Mayo Clinic Rochester. RESULTS Autoimmune cytopenia responded in 19 patients (14 CR and 5 PR) with a median time to progression (TTP) of 13.6 months (range 5 – 29). Five patients remain in sustained remission at last follow up (range 15 – 30 months) and 4 patients have had recurrent autoimmune cytopenia requiring re-treatment. Six patients required maintenance corticosteroid therapy after completing R-CVP. Progressive CLL responded to treatment in 17 patients (9 CR/CCR, 8 PR by NCI-WG 1996 criteria) with a median TTP of 6.3 months (range 1-40 months). Fourteen patients have required additional treatment for progressive CLL at a median of 5.4 months (range 4-22 months). Five patients have not required additional treatment for either CLL or autoimmune cytopenia at 15 -30 months after completing treatment. R-CVP treatment toxicity included 3 patients with grade 3-4 infections, 2 with grade 1 peripheral neuropathy, and one with grade 3 drug-induced pneumonitis. No patient required blood cell transfusions after the completion of cycle 1 of therapy. CONCLUSIONS Although R-CVP is an effective and tolerable therapy for patients with simultaneous autoimmune cytopenia and progressive CLL requiring therapy, the duration of response is suboptimal. Clinical trials testing alternative treatment strategies are needed for this patient population. Disclosures: Zent: Genentech, Bayer, Genzyme, Novartis: Research Funding. Shanafelt:Cephalon: Research Funding; Celgene: Research Funding; Polyphenon Pharma : Research Funding; Hospira: Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Research Funding; Bayer Health Care Pharmaceuticals: Research Funding. Kay:Biogenc-Idec, Celgene, Genentech, genmab: Membership on an entity's Board of Directors or advisory committees; Genentech, Celgene, Hospira, Polyphenon Pharma, Sanofi-Aventis: Research Funding.

The objective: to assess and compare supraglottic airways of LMA-Supreme and i-gel during orbital osteosynthesis.Subjects and methods. 91 patients were included into the study. All of them underwent osteosynthesis of the orbit. The patients were randomly divided into two groups. LMA-Supreme group included 42 patients, while i-gel group included 49 patients.Results. The parameters of hemodynamics, gas exchange, and artificial pulmonary ventilation (APV) did not basically differ between the groups at different stages of the study. The oropharyngeal leak pressure differed between the groups at the end of surgery and made (Me – median, Q1 and Q3 – upper and lower quartiles): 28.0 (22.0; 30.0) and 21.0 (19.0; 27.0) mm WG the LMA-Supreme and i-gel groups, respectively; p = 0.021. A significant difference was observed in the insertion time of supraglottic airways (Me is the median, Q1 and Q3 are the upper and lower quartiles): 27.5 (19.3; 36.5) sec. for LMA-Supreme and 15.0 (13.8; 25.0) sec. – for i-gel; p = 0.001. When inserting the LMA-Supreme duct in 33 (78.6%) patients, jaw thrust maneuver, extension of the neck, etc. were required; while in the i-gel group, similar maneuvers were necessary in 18 (36.7%) patients; p < 0.001. The number of postoperative complications was minimal in both groups.Conclusion. Both supraglottic airways can be used with equal efficacy in osteosynthesis of the orbit. At the same time, the i-gel duct has an advantage over the LMA-Supreme in speed and simplicity of insertion. The LMA-Supreme had greater leak pressure at the end of surgery, which might be an advantage in patients requiring greater peak inspiratory pressure to provide effective APV.

Zahlreiche pathogene „missense“-Mutation, die verhindern, dass Proteine korrekt gefaltet werden, befinden sich in geordneten Regionen von Proteinen. Andere krankheitsrelevante Mutationen befinden sich in ungeordneten Regionen und beeinflussen somit nur begrenzt die Funktionalität, zum Beispiel durch Veränderungen kurzer linearer Sequenzmotive, die Protein-Protein Interaktionen vermitteln. In dieser Arbeit wird ein peptidbasierter Interaktionsscreen präsentiert mit dem sich Veränderungen im Interaktom identifizieren lassen. Synthetische Peptide von wild-typ und zugehörigen mutierten Proteinregionen ermöglichen die gleichzeitige Untersuchung von mehr als hundert Mutationen mittels Massenspektrometrie. Mehr als ein Drittel aller getesteten Mutationen hatten veränderte Interaktionen zur Folge. Darunter befanden sich auch drei Prolin zu Leucin Mutationen in zytosolischen Regionen von Transmembranproteinen, die zusammen mit dem benachbarten Leucin einem Dileucinmotiv ergeben und dadurch verstärkt mit Clathrin interagieren. Dieses Motiv wurde bereits mit Clathrin-vermittelter Endozytose in Verbindung gebracht. Die hinzugewonnene Endozytose könnte Krankheitsmechanismen erklären, da die Mislokalisation der betroffenen Transmembranproteine zum effektiven Verlust derer Funktion führen würde. Diese Hypothese wurde hier von verschiedenen in vitro und in vivo Experimenten bezüglich der P485L Mutation im Glukose Transporter-1 (GLUT1), die das GLUT1-Defizit-Syndrom hervorruft, bestätigt. Weitere Evidenz wurde außerdem für die Funktionalität anderer mutationsbedingter Dileucinmotive gewonnen. Die systematische Analyse von pathogenen Mutationen hat gezeigt, dass Dileucinmotive signifikant und spezifisch in ungeordneten zytosolischen Regionen von Transmembranproteinen überrepräsentiert sind. Dieser Peptidescreen macht das Potenzial unvoreingenommener Analysen zur Aufklärung von Krankheitsmechanismen deutlich, die von Veränderungen in Protein-Protein Interaktionen hervorgerufen werden.
Many disease-associated missense mutations prevent proteins from folding correctly and lead to loss-of-function. These mutations are often found in ordered regions of proteins. Another class of disease-related missense mutations can be found in disordered regions. These are thought to impair only specific parts of a protein’s functions. Those mutations could modify short linear motifs that mediate protein-protein interactions. Here, we designed a peptide-based interaction screen to identify interactions that are affected by mutations in disordered regions. We used synthetic peptides corresponding to the wild type and mutated protein regions spotted on cellulose membrane to pull-down interaction partners. This setup allows for the screening of more than hundred mutations at a time via mass spectrometry. Here, we focused on mutations implicated in neurological diseases. More than one-third of tested variant pairs show differential interactions. Three disease-related proline to leucine mutations in cytosolic tails of transmembrane proteins lead to gain of a dileucine sequence. Several dileucine-containing peptide motifs are involved in clathrin-mediated endocytosis (CME). Also in the presented screen, the newly created motifs mediate interaction with the CME machinery. This could explain the disease mechanisms since mislocalization of the affected transmembrane proteins would lead to their loss of function. This hypothesis has been corroborated for glucose transporter-1 (GLUT1) P485L, causing GLUT1 deficiency syndrome. We were able to provide functional evidence also for additional gained dileucine motifs. A systematic analysis of pathogenic mutations revealed dileucine motifs to be overrepresented in structurally disordered cytosolic regions of transmembrane proteins. The data gained with the peptide screen highlights the power of differential interactome mapping as a generic approach to unravel disease mechanisms caused by changes in protein-protein interactions.

The main contributor to the high-cycle fatigue of compressor blades is the response to aerodynamic forcing functions generated by an upstream row of stators or inlet guide vanes. Resonant response to engine order excitation at certain rotor speeds is especially damaging. Studies have shown that flow control by trailing edge blowing (TEB) can reduce stator wake strength and the amplitude of the downstream rotor blade vibrations generated by the unsteady stator-rotor interaction. In the present study, the effectiveness of TEB to reduce forced blade vibrations was evaluated in a modern transonic compressor rig. A row of wake generator (WG) vanes with TEB capability was installed upstream of the rotor, which was instrumented with strain gages. Data was collected with and without TEB at various rotor speeds involving resonance crossings. Using 0.8% of the compressor core flow for TEB along the full WG-span, rotor blade strain was reduced by 66% at the first torsional resonance crossing. Substantial reductions were also achieved with only partial span TEB. The results demonstrate the effectiveness of the TEB technique for reducing rotor vibrations in the complex flow environment of a closely-spaced transonic stage row. Moderate increases in stage performance were also measured.

In support of potential licensing of the mixed oxide (MOX) fuel made from weapons-grade (WG) plutonium and depleted uranium for use in United States reactors, an experiment containing WG-MOX fuel is being irradiated in the Advanced Test Reactor (ATR) at the Idaho National Engineering and Environmental Laboratory (INEEL). The WG-MOX comprises five percent PuO2 and 95% depleted UO2. Based on the Post Irradiation Examination (PIE) observation, the volume fraction (VF) of MOX agglomerates in the fuel pellet is about 16.67%, and PuO2 concentration of 30.0 = (5 / 16.67 × 100) wt% in the agglomerate. A pressurized water reactor (PWR) unit WG-MOX lattice with Agglomerate-by-Agglomerate Fuel (AbAF) modeling has been developed. The effect of the irregular agglomerate distribution can be addressed through the use of the Monte Carlo AbAF model. The AbAF-calculated cumulative ratio of AGglomerate burnup to U-MAtrix burnup (AG/MA) is 9.17 at the beginning of life (BOL), and decreases to 2.88 at 50 GWd/t. The MCNP-AbAF-calculated results can be used to adjust the parameters in the MOX fuel fission gas release modeling.